Dynavax Technologies Corporation vs Taro Pharmaceutical Industries Ltd.: Examining Key Revenue Metrics

Dynavax vs. Taro: A Decade of Revenue Dynamics

__timestampDynavax Technologies CorporationTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201411032000759285000
Thursday, January 1, 20154050000862944000
Friday, January 1, 201611043000950751000
Sunday, January 1, 2017327000879387000
Monday, January 1, 20188198000661913000
Tuesday, January 1, 201935219000669893000
Wednesday, January 1, 202046551000644769000
Friday, January 1, 2021439442000548970000
Saturday, January 1, 2022722683000561347000
Sunday, January 1, 2023232284000572952000
Monday, January 1, 2024629182000
Loading chart...

Cracking the code

A Tale of Two Companies: Dynavax vs. Taro

In the ever-evolving pharmaceutical landscape, Dynavax Technologies Corporation and Taro Pharmaceutical Industries Ltd. present a fascinating study in contrasts. Over the past decade, Dynavax has experienced a meteoric rise, with revenue surging by over 6,400% from 2014 to 2022. This growth is largely attributed to their innovative vaccine solutions, which have captured significant market share.

Conversely, Taro has maintained a steady revenue stream, averaging around $700 million annually. Despite a slight dip in 2021, Taro's revenue rebounded by 15% in 2023, showcasing its resilience in the face of market fluctuations.

While Dynavax's revenue trajectory is marked by volatility, Taro's consistent performance underscores its stability. As we look to the future, the missing data for 2024 leaves room for speculation on how these industry players will adapt to new challenges and opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025